TY  - JOUR
AU  - Karneboge, Jonas
AU  - Haberstroh, Julia
AU  - Geschke, Katharina
AU  - Perry, Julia
AU  - Radenbach, Katrin
AU  - Jessen, Frank
AU  - Rostamzadeh, Ayda
TI  - Facing the new diagnostic and treatment options of Alzheimer's disease: The necessity of informed consent.
JO  - Alzheimer's and dementia
VL  - 21
IS  - 1
SN  - 1552-5260
CY  - Hoboken, NJ
PB  - Wiley
M1  - DZNE-2025-00281
SP  - e14204
PY  - 2025
AB  - With advances in biomarker-based detection of Alzheimer's disease (AD) and new treatment options with disease-modifying treatments (DMTs), we are heading toward a new conceptualization of diagnostics and therapy in the early stages of AD. Yet consensus guidelines on best clinical practices in predictive AD diagnostics are still developing. Currently, there is a knowledge gap regarding counseling and disclosure practices in early symptomatic disease stages, its implications for dementia risk estimation, and DMTs with associated risks and benefits. The crucial feature is the capacity of patients with (mild) cognitive impairment, eligible for DMTs, to consent. This perspective aims to (1) discuss the current challenges in assessing capacity to consent and (2) highlight the importance of a supported (informed) decision-making process. Measures to facilitate informed decision-making of patients constitute an ethical approach to enhancing the quality of care in this evolving therapeutic landscape. HIGHLIGHTS: This perspective: Explores biomarker-based early symptomatic AD detection and the implications for patient care. Emphasizes supported decision-making in DMTs for MCI and dementia patients. Discusses the need for standardized tools to assess the capacity to consent. Aligns diagnostic and treatment approaches with ethical care standards. Enhances patient autonomy in the evolving AD therapeutic landscape.
KW  - Humans
KW  - Alzheimer Disease: diagnosis
KW  - Alzheimer Disease: therapy
KW  - Alzheimer Disease: drug therapy
KW  - Informed Consent
KW  - Biomarkers
KW  - Cognitive Dysfunction: diagnosis
KW  - Cognitive Dysfunction: therapy
KW  - Decision Making
KW  - Mental Competency
KW  - anti‐amyloid therapy (Other)
KW  - biomarkers (Other)
KW  - capacity to consent (Other)
KW  - communication (Other)
KW  - dementia risk estimation (Other)
KW  - early diagnosis (Other)
KW  - informed consent (Other)
KW  - supported decision‐making (Other)
KW  - Biomarkers (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:39740107
C2  - pmc:PMC11772727
DO  - DOI:10.1002/alz.14204
UR  - https://pub.dzne.de/record/276318
ER  -